TESTING OPTION FOR PROSTATE CANCER
Adjunct to serum prostate specific antigen (PSA) for risk stratification of patients undergoing prostate biopsy. MPS incorporates serum PSA, urine PCA3 score, and urine TMPRSS2: ERG score in logistic regression models to derive scores giving the risk of detecting high grade (Gleason score >7) prostate cancer on diagnostic needle biopsy.
BRAC Mutation Panel
TESTING OPTION FOR BREAST, OVARIAN, PROSTATE, PANCREATIC CANCERS
BRCA Panel analysis can be performed on a patient who has a family history or is suspected of having breast, ovarian, prostate, or pancreatic cancer or for determining a genetic mutation for a patient with a clinical diagnosis of one of these cancers. Germline mutations in the BRCA1 and/or BRCA2 genes are associated with an increased risk for these cancers.
Melanoma NGS Panel
TESTING OPTION FOR METASTATIC MELANOMA
Molecular testing of metastatic melanoma is currently the standard of care for guiding the use FDA-approved targeted therapies such as BRAF, MEK and KIT inhibitors. This assay is designed to provide comprehensive molecular results relevant for both standard of care and emerging/investigational clinical actions.
KIT Mutation - Exon 9, 11, 13,17
TESTING OPTION FOR GASTRONINTESTINAL STROMAL TUMOR
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Most GISTs characteristically express the KIT receptor tyrosine kinase, and approximately 80% harbor oncogenic mutations within the KIT gene. All mutations result in the constitutive activation of KIT, which has led to the use of tyrosine kinase inhibitor drugs (imatinib) as a common therapy for GIST patients.
FOR ALL YOUR LABORATORY NEEDS
Genetic analyses to drive more specific cancer diagnoses and more precise treatment plans. Includes single gene assays and multiple gene test panels for more than a dozen cancer types.
Comprehensive DNA-based testing to diagnose and manage a range of inherited diseases. Includes single-gene germline testing modalities for a range of rare syndromes.
Provide highly specialized evaluations for the most comprehensive, contemporary diagnosis of in renal, neuromuscular and dermatopathoogy.
Profiling the genetic drivers of a range of inherited childhood illnesses through germline testing, including gene sequencing and chromosomal microarray analysis.
MEET DR. BROWN
EXPERTISE DELIVERED PERSONALLY
The field of molecular oncology is exploding as we discover more and more about the genetic origins of diseases like cancer. Relatively few facilities are able to keep up with the pace of genetic technology like next generation sequencing. MLabs brings a full portfolio of molecular tests to help small community hospitals and labs offer their patients state-of-the-art care.
Noah Brown, M.D.
Associate Professor of Pathology
Director, Molecular Diagnostics